Literature DB >> 15350180

Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants.

C G Korkmaz1, K Frønsdal, Y Zhang, P I Lorenzo, F Saatcioglu.   

Abstract

Androgens are critical in the development and maintenance of the male reproductive system and important in the progression of prostate cancer. The effects of androgens are mediated by the androgen receptor (AR), which is a ligand-modulated transcription factor that belongs to the nuclear receptor superfamily. We and others have previously shown that CREB-binding protein (CBP) can function as a coactivator for AR. Similar to some other nuclear receptor coactivators and/or the proteins that they interact with, CBP has histone acetyl transferase (HAT) activity that is thought to contribute to transcriptional activation by nuclear receptors. We have therefore assessed whether an increase in the histone acetylation status in the cell can influence AR transcriptional activity, by using the histone deacetylase (HDAC) inhibitors (HDACIs) trichostatin A (TSA), sodium butyrate (Na-But) and depsipeptide (FR901228). We found that inhibition of HDAC activity significantly increased the ability of endogenous AR in LNCaP cells, or ectopically expressed AR in HeLa cells, to activate transcription from AR-dependent reporter constructs. In addition, HDACIs increased the androgen-dependent activation of the prostate-specific antigen (PSA) gene in LNCaP cells, an increase that was not due to an increase in nuclear AR protein levels. Moreover, the viral oncoprotein E1A that inhibits CBP HAT activity fully repressed the ability of HDACIs to stimulate AR-mediated transcription, indicating that CBP is involved in this process. Deletional mutagenesis of AR indicated that whereas the AF-2 domain in the C-terminus is dispensable, the AF-1 domain in the N-terminus is required for augmentation of AR action by HDACIs, an observation which is in concordance with the reduced ability of CBP to activate AR N-terminal deletion mutants. Furthermore, HDACI treatment rescued the deficiency in the transactivation potential of AF-2 mutants. Taken together, our findings suggest that a change in the level of histone acetylation of target genes is an important determinant of AR action, possibly mediated by CBP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350180     DOI: 10.1677/joe.0.1820377

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  22 in total

1.  KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling.

Authors:  Wei He; Min-Guang Zhang; Xiao-Jing Wang; Shan Zhong; Yuan Shao; Yu Zhu; Zhou-Jun Shen
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

2.  Divergent Binding and Transactivation by Two Related Steroid Receptors at the Same Response Element.

Authors:  Martina Tesikova; Xavier Dezitter; Hatice Z Nenseth; Tove I Klokk; Florian Mueller; Gordon L Hager; Fahri Saatcioglu
Journal:  J Biol Chem       Date:  2016-04-07       Impact factor: 5.157

3.  Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.

Authors:  John D Clarke; Anna Hsu; Zhen Yu; Roderick H Dashwood; Emily Ho
Journal:  Mol Nutr Food Res       Date:  2011-03-04       Impact factor: 5.914

Review 4.  Dietary factors and epigenetic regulation for prostate cancer prevention.

Authors:  Emily Ho; Laura M Beaver; David E Williams; Roderick H Dashwood
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

Review 5.  Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling.

Authors:  Vineela Kadiyala; Catharine L Smith
Journal:  Mol Endocrinol       Date:  2014-03-19

6.  Ligand-specific dynamics of the androgen receptor at its response element in living cells.

Authors:  Tove I Klokk; Piotr Kurys; Cem Elbi; Akhilesh K Nagaich; Anindya Hendarwanto; Thomas Slagsvold; Ching-Yi Chang; Gordon L Hager; Fahri Saatcioglu
Journal:  Mol Cell Biol       Date:  2006-12-22       Impact factor: 4.272

7.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.

Authors:  Derek S Welsbie; Jin Xu; Yu Chen; Laetitia Borsu; Howard I Scher; Neal Rosen; Charles L Sawyers
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

Review 9.  Targeting the androgen receptor pathway in prostate cancer.

Authors:  Yu Chen; Charles L Sawyers; Howard I Scher
Journal:  Curr Opin Pharmacol       Date:  2008-08-12       Impact factor: 5.547

10.  Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.

Authors:  Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria J Sinibaldi; Janet S Walczak; Samuel R Denmeade
Journal:  Cancer Biol Ther       Date:  2007-06-05       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.